Evidence for HLA-related susceptibility for stroke in children with sickle cell disease

Blood

Volumn 95, Issue 11, 2000, Pages 3562-3567

  Styles, Lori A ^a   Hoppe, Carolyn ^b   Klitz, William ^b   Vichinsky, Elliott ^b   Lubin, Bertram ^b   Trachtenberg, Elizabeth ^b  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; BRAIN INFARCTION; CONTROLLED STUDY; DISEASE PREDISPOSITION; HEREDITY; HLA TYPING; HUMAN; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; SICKLE CELL ANEMIA;

EID: 0034210945     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.11.3562.011k49_3562_3567     Document Type: Article

References (61)

1. Moser FG, Miller ST, Bello JA, et al. The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. Am J Neuroradiol. 1996;17: 965-972.
2. Ohene-Frempong K. Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations. Semin Hematol. 1991;28:213-219.
3. Kinney TR, Sleeper LA, Wang WC, et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. Pediatrics. 1999;103:640-645.
4. Craft S, Schatz J, Glauser TA, et al. Neuropsychologic effects of stroke in children with sickle cell anemia. J Pediatr. 1993;123:712-717.
5. Armstrong FD, Thompson RJ, Wang W, et al. Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease. Pediatrics. 1996;97:864-870.
6. Powars D, Wilson B, Imbus C, et al. The natural history of stroke in sickle cell disease. Am J Med. 1978;65:461-471.
7. Pavlakis SG. Neurologic complications of sickle cell disease. Adv Pediatr. 1989;36:247-276.
8. Stockman JA, Nigro MA, Mishkin MM, Oski FA. Occlusion of large cerebral vessels in sickle-cell anemia. N Engl J Med. 1972;287:846-849.
9. Wiznitzer M, Ruggieri PM, Masaryk TJ, Ross JS, Modic MT, Berman B. Diagnosis of cerebrovascular disease in sickle cell anemia by magnetic resonance angiography. J Pediatr. 1990;117:551-555.
10. Gerald B, Sebes JI, Langston JW. Cerebral infarction secondary to sickle cell disease: arteriographic findings. Am J Radiol. 1980;134:1209-1212.
11. Koshy M, Thomas C, Goodwin J. Vascular lesions in the central nervous system in sickle cell disease (neuropathology). J Am Assoc Minority Physicians. 1990;1:71-78.
12. Hebbel RP, Boogaerts MA, Eaton JW, Steinberg MH. Erythrocyte adherence to endothelium in sickle-cell anemia: a possible determinant of disease severity. N Engl J Med. 1980;302:992-995.
13. Hebbel RP. Perspectives series: cell adhesion in vascular biology: adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest. 1997;99:2561-2564.
14. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med. 1997;337: 1584-1590.
15. Mohandas N, Evans E. Adherence of sickle erythrocytes to vascular endothelial cells: requirement for both cell membrane changes and plasma factors. Blood. 1984;64:282-287.
16. Russell MO, Goldberg HI, Hodson A, et al. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood. 1984;63:162-169.
17. Driscoll M, Hurlet A, Berman B, Files B, Byrne J. Stroke in SIB-pairs with sickle cell disease [abstract]. Blood. 1997;90:264a.
18. Kahn MJ, Scher C, Rozans M, Michaels RK, Leissinger C, Krause J. Factor V Leiden is not responsible for stroke in patients with sickling disorders and is uncommon in African Americans with sickle cell disease. Am J Hematol. 1997;54: 12-15.
19. De Castro L, Rinder HM, Howe JG, Smith BR. Thrombophilic genotypes do not adversely affect the course of sickle cell disease (SCD) [abstract]. Blood. 1998;92:1613.
20. Rahimy MC, Krishnamoorthy R, Ahouignan G, Laffan M, Vulliamy T. The 20210A allele of prothrombin is not found among sickle cell disease patients from West Africa. Thromb Haemost. 1998;79:444-445.
21. Dahlen G, Slunga L, Lindblom B. Importance of Lp(a) lipoprotein and HLA genotypes in atherosclerosis and diabetes. Clin Genet. 1994;46: 46-51.
22. Dahlen GH, Boman J, Birgander LS, Lindblom B. Lp(a) lipoprotein, IgG, IgA, and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis. 1995;114:165-174.
23. Barst RJ, Flaster ER, Menon A, Fotino M, Morse JH. Evidence for the association of unexplained pulmonary hypertension in children with the major histocompatibility complex. Circulation. 1992;85: 249-258.
24. Morse JH, Barst RJ, Fotino M, et al. Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7. Am J Respir Crit Care Med. 1997;155:274-278.
25. Inoue T, Ikezaki K, Sasazuki T, Matsushima T, Fukui M. Analysis of class II genes of human leukocyte antigen in patients with moyamoya disease. Clin Neurol Neurosurg. 1997;99(suppl 2): S234-237.
26. Just JJ, King MC, Thomson G, Klitz W. African-American HLA class II allele and haplotype diversity. Tissue Antigens. 997;49:547-555.
27. Schart SJ, Griffith RL, Erlich HA. Rapid typing of DNA sequence polymorphism at the HLA-DRB1 locus using the polymerase chain reaction and nonradioactive oligonucleotide probes. Hum Immunol. 1991;30:190-201.
28. Moonsamy PV, Aldrich C, Petersdorf E, Hill AV, Begovich A. Seven new DPB1 alleles and their population distribution. Tissue Antigens. 1994;43: 249-252.
29. Trachtenberg EA, Keyeux G, Bernal JE, Rhodas MC, Erlich HA. Results of Expedicion Humana, I: analysis of HLA class II (DRB1-DQA1-DPB1) alleles and DR-DQ haplotypes in nine Amerindian populations from Colombia. Tissue Antigens. 1996;48:174-184.
30. Begovich AB, McClure GR, Suraj VC, et al. Polymorphism, recombination, and linkage disequilibrium within the HLA class II region. J Immunol. 1992;148:249-258.
31. Imanishi T, Akaza T, Kimura K, Tokunaga K, Gojoberi T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T, eds. HLA 1991. Oxford, England: Oxford University Press; 1992: 1065-1220.
32. Bugawan TL, Apple R, Erlich HA. A method for typing polymorphism at the HLA-A locus using PCR amplification and immobilized oligonucleotide probes. Tissue Antigens. 1994;44:137-147.
33. Trachtenberg EA, Bugawan TL, Apple R, Castro R, Erlich HA. Efficient typing of the HLA-B locus using the PCR and immobilized oligonucleotide probes. Hum Immunol. 1994;40:43-50.
34. Bodmer JG, Marsh SG, Albert ED, et al. Nomenclature for factors of the HLA system, 1996. Tissue Antigens. 1997;49:297-321.
35. Sokal R, Rohlt F. Biometry: The Principles and Practice of Statistics in Biological Research. San Francisco, CA: W. H. Freeman; 1981.
36. Klitz W, Stephens JC, Grote M, Carrington M. Discordant patterns of linkage disequilibrium of the peptide-transporter loci within the HLA class II region. Am J Hum Genet. 1995;57:1436-1444.
37. Thorsby E. HLA associated diseases. Hum Immunol. 1997;53:1-11.
38. Svejgaard A, Fugger L, Garred P, Madsen HO, Ryder LP. Associations between HLA and disease with notes on additional associations between a "new" immunogenetic marker and rheumatoid arthritis. Munksgaard, Copenhagen: Academic Press. 1997;301-313.
39. Chang YP, Maier-Redelsperger M, Smith KD, et al. The relative importance of the X-linked FCP locus and beta-globin haplotypes in determining haemoglobin F levels: a study of SS patients homozygous for beta S haplotypes, Br J Haematol. 1997;96:806-814.
40. Powars DR, Meiselman HJ, Fisher TC, Hiti A, Johnson C. Beta-S gene cluster haplotypes modulate hematologic and hemorheologic expression in sickle cell anemia: use in predicting clinical severity. Am J Pediatr Hematol Oncol. 1994;16:55-61.
41. Piomelli S, Seaman C, Cirella B, et al. Does α-thalassemia protect from early stroke in sickle cell anemia? [abstract], Pediatr Res. 1986;10: 285a.
42. Adams RJ, Kutlar A, McKie V, et al. Alpha thalassemia and stroke risk in sickle cell anemia. Am J Hematol. 1994;45:279-282.
43. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288-294.
44. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class Mike gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996; 13:399-408.
45. Hill AVS, Allsopp CEM, Kwiatkowski D, et al. Common West African HLA antigens are associated with protection from severe malaria. Nature. 1991;352:595-600.
46. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
47. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today. 1995;16:27-33.
48. Masuda J, Ogata J, Yutani C. Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease. Stroke. 1993;24:1960-1967.
49. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
50. Francis RB. Large-vessel occlusion in sickle cell disease: pathogenesis, clinical consequences, and therapeutic implications. Med Hypotheses. 1991;35:88-95.
51. Hebbel RP. Beyond hemoglobin polymerization: the red blood cell membrane and sickle disease pathophysiology. Blood. 1991;77:214-237.
52. Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest. 1998;101:1899-1904.
53. Sowemimo-Coker SO, Meiselman HJ, Francis RB Jr. Increased circulating endothelial cells in sickle cell crisis. Am J Hematol. 1989;31:263-265.
54. Belcher JD, Marker PH, Weber J, Hebbel RP, Vercellotti GM. Upregulation of NFκB, tissue factor, E-selectin, and neutrophil adhesion in endothelial cells incubated with monocytes and red blood cells from sickle cell anemia patients [abstract]. Blood. 1998;92:496a.
55. Pober JS. The endothelium as an antigen presenting cell. In: Hansson GK, Libby P, eds. Immune Functions of the Vessel Wall, vol. 2, Advances in Vascular Biology. Amsterdam, Netherlands: Harwood Academic Publishers; 1996:1-27.
56. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr. 1992;120:360-366.
57. Wilimas J, Goff JR, Anderson HR, Langston JW, Thompson E. Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents. J Pediatr. 1980;96:205-208.
58. Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 1995;126:896-899.
59. Walters MC, Patience M, Leisenring W, et al. Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions. Biol Blood Marrow Transplant. 1997;3:310-315.
60. Adams R, McKie V, Nichols F, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med. 1992;326:605-610.
61. Adams R, McKie V, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonagraphy. N Engl J Med. 1998; 339:5-11.